Follows Unprecedented Reverse and Remand of PTAB Decision at Federal Circuit
In a decision that may pave the way to fend off future invalidity challenges, attorneys from Mintz, Cohn, Ferris, Glovsky and Popeo, P.C. secured another victory for their client Straight Path IP Group. The U.S. Patent Trial and Appeal Board (PTAB) ruled in Straight Path’s favor in six Inter Partes Reviews (IPRs) challenging the validity of three Straight Path patents, upholding the validity of claims in all three challenged patents.
In its decision, PTAB determined that petitioners Cisco Systems, Inc., Avaya, Inc., Samsung Electronics Co., Ltd., Samsung Electronics America, Inc., and Samsung Telecommunications America, LLC failed to prove the unpatentability of all challenged claims in two Straight Path patents and seven of the ten challenged claims in a third.
“This is a significant win for our client and further reinforces the value and quality of Straight Path’s patents. These victories also bode well for Straight Path prevailing in the remaining IPRs pending against its patents,” said William A. Meunier, a Member of the Intellectual Property Section.
In addition to Mr. Meunier, Straight Path was represented by Michael T. Renaud, Division Head for the IP section and a member of Mintz’s Policy Committee and Mintz IP Members Michael C. Newman, Michael J. McNamara, James Wodarski and associate Nicholas W. Armington .
In recent months Mintz’s IP group recently secured two additional IPR successes on behalf of their clients. In November, the PTAB issued a Final Written Decision invaliding all of the claims challenged in an IPR Petition the firm submitted on behalf of ACE Bed Co. Ltd. challenging the validity of a patent assigned to Sealey Technology LLC relating to bed springs. Prior to that, the PTAB handed down a decision in favor of firm client and Respondent Kowa Company. Mylan, a generic pharmaceutical manufacturer, had filed an IPR in an attempt to invalidate claims integral to Kowa Company’s drug Livalo, and the PTAB declined to institute.